Acamprosate for the adjunctive treatment of alcohol dependence

Annals of Pharmacotherapy

Volumn 37, Issue 7-8, 2003, Pages 1090-1099

  Overman, Gerald P ^a,c   Teter, Christian J ^b   Guthrie, Sally K ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NONE

Author keywords

Acamprosate; Alcohol dependence

Indexed keywords

ACAMPROSATE; ALCOHOL; AMINO ACID; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; DISULFIRAM; HOMOTAURINE; HYPNOTIC AGENT; NALTREXONE; NEUROLEPTIC AGENT;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALCOHOLISM; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE COST; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MEDLINE; MULTICENTER STUDY; NAUSEA; NEUROTRANSMISSION; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; PSYCHOTHERAPY; RASH; REVIEW; VERTIGO; VOMITING;

EID: 0037765109     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C351     Document Type: Review

References (62)

1. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999;281:1318-25.
2. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999;340:1482-90.
3. Acamprosate. In: Sweetman SC, ed. Martindale: the complete drug reference. 33rd ed. Chicago: Pharmaceutical Press, 2002:653-4.
4. Chick J. Acamprosate as an aid in the treatment of alcoholism. Alcohol Alcohol 1995;30:785-7.
5. Acamprosate Summary Sheet. MTRAC, Department of Medicines Management, Keele University, Keele, Staffordshire, May 1997. www.ukmicentral.nhs.uk/pressupp/sd.asp (accessed 2002 Aug 1).
6. Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: an overview. In: Soyka M, ed. Acamprosate in relapse prevention of alcoholism. Berlin. Germany: Springer-Verlag, 1996:47-64.
7. West SL, Garbutt JC, Carey TS, Lux LJ, Jackman AM, Tolleson-Rinehart S, et al. Pharmacotherapy for alcohol dependence: evidence report no. 3. Rockville, MD: Agency for Health Care Policy and Research, 1999, AHCPR publication 99-E004.
8. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate. J Clin Psychiatry 2001;62(suppl 20):S42-8.
9. Gewiss M, Heidbreder C, Opsomer L, Durbin P, De Witte P. Acamprosate and diazepam differentially modulate alcohol-induced behavioural and cortical alterations in rats following chronic inhalation of ethanol vapour. Alcohol Alcohol 1991;26:129-37.
10. Spanagel R, Zieglgansberger W, Hundt W. Acamprosate and alcohol: III. effects on alcohol discrimination in the rat. Eur J Pharmacol 1996;305:51-6.
11. Grant KA, Woolverton WL. Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals. Pharmacol Biochem Behav 1989;32:607-11.
12. Le Magnen J, Tran G, Durlach J, Martin C. Dose-dependent suppression of the high alcohol intake of chronically intoxicated rats by Ca-acetyl homotaurinate. Alcohol 1987;4:97-102.
13. Daoust M, Legrand E, Gewiss M, Heidbreder C, DeWitte P, Tran G, et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992;41:669-74.
14. Gerra G, Caccavari R, Delsignore R. Pituitary responses to Ca-acetyl homotaurinate in normal subjects and alcoholics. Neuroendocrinol Lett 1992;14:119-26.
15. Zieglgansberger W, Hauser C, Putzke J, Spanagel R, Wetzel C. The enhanced excitability of central neurons following chronic alcohol intake is reduced by acamprosate (abstract C10.22). Presented at: the 5th Congress of the European Society for Biomedical Research on Alcoholism (ESBRA), Stuttgart, Germany, September 6-9, 1995. Alcohol Alcohol 1995;30:552.
16. Zieglgansberger W, Hauser C, Wetzel C, Putzke J, Siggins GR, Spanagel R. Actions of acamprosate on neurons of the central nervous system. In: Soyka M, ed. Acamprosate in relapse prevention of alcoholism. Berlin, Germany: Springer-Verlag, 1996:65-70.
17. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 1993;231:47-52.
18. Dahchour A, De Witte P, Bolo N, Nedelec JF, Muzet M, Durbin P, et al. Central effects of acamprosate. Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 1998;82:107-14.
19. +-induced calcium flux into cortical neurons in vitro (abstract 531). Alcohol Clin Exp Res 1996;20:92A.
20. al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part 11. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res 1998;22:810-4.
21. Berton F, Francesconi WG, Madamba SG, Zieglgansberger W, Siggins GR. Acamprosate enhances N-methyl-D-aspartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res 1998;22:183-91.
22. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. Eur J Pharmacol 2002;437:55-61.
23. Schneider U, Wohlfarth K, Schulze-Bonhage A, Haacker T, Caspary A, Zedler M, et al. Lack of psychotomimetic of impairing effects on psychomotor performance of acamprosate. Pharmacopsychiatry 1998;31:110-3.
24. Schneider U, Wohlfarth K, Schulze-Bonhage A, Haacker T, Muller-Vahl KR, Zedler M, et al. Effects of acamprosate on memory in healthy young subjects. J Studies Alcohol 1999;60:172-5.
25. Soyka M, Aichmuller C, Preuss U, Moller HJ. Effects of acamprosate on psychomotor performance and driving ability in abstinent alcoholics. Pharmacopsychiatry 1998;31:232-5.
26. Schule C, Laakmann G, Baghai T, Neukam C, Soyka M. Lack of effects of acamprosate on anterior pituitary hormone secretion in healthy subjects. J Clin Psychopharmacol 1999;19:387-9.
27. Zimmerman U, Hundt W, Grabner A, Hahn K, Holsboer F. Effect of acamprosate on the hypothalamic-pituitary-adrenal (HPA) system in early abstinent alcoholics (abstract E5.010). Presented at: the 12th European College of Neuropsychopharmacology (ECNP) Conference, London, UK. September 21-25, 1999. Eur Neuropsychopharmacol 1999;9:336.
28. Bolo N, Nedelec JF, Muzet M, De Witte P, Dahchour A, Durbin P, et al. Central effects of acamprosate. Part 2. Acamprosate modifies the brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatry Res 1998;82:115-27.
29. Wohlfarth K, Schneider U, Haacker T, Schubert M, Schulze-Bonhage A, Zedler M, et al. Acamprosate reduces motor cortex excitability determined by transcranial magnetic stimulation. Neuropsychobiology 2000;42:183-6.
30. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G, Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998;35:331-45.
31. Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E. Korean acamprosate clinical trial investigators. Acamprosate in Korean alcohol-dependent patients: a multicentre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 2003:38:135-41.
32. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo controlled study in Spain. Alcohol Alcohol 2001;36:413-8.
33. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a six-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 2000;35:176-87.
34. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 2000;35:202-9.
35. Poldrugo F. Acamprosate treatment in a long-term, community-based alcohol rehabilitation programme. Addiction 1997:92:1537-46.
36. Barrias JA, Chabac S, Ferreira L, Fonte A, Potgieter AS. Teixeira de Sousa E. [Acamprosate: multicentre Portuguese efficacy and tolerance evaluation study]. Portuguese. Psiquiatria Clinica 1997;18:149-60.
37. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 1997;3:129-37.
38. Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. Br J Psychiatry 1997;171:73-7.
39. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996;347:1438-42.
40. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996;53:673-80.
41. Paille FM, Guelfi JD, Perkind AC, Royer RJ, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 1995;30:239-47.
42. Pelc I, Le Bon O, Verbanck P, Lehert P, Opsomer L. Calcium-acetylhomotaurine for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multicenter trial. In: Naranjo C, Sellers E, eds. Novel pharmacological interventions for alcoholism. New York: Springer-Verlag, 1992:348-52.
43. Lhuintre JP, Moore N, Tran G, Steru L, Langrenon S, Daoust M, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990;25:613-22.
44. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985;1:1014-6.
45. O'Brien CP, Eckardt MJ, Linnoila VMI. Pharmacotherapy of alcoholism. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology, the fourth generation of progress. New York: Raven Press, 1995:1745-56.
46. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980.
47. Diagnostic and statistical manual of mental disorders. 3rd ed. revised. Washington, DC: American Psychiatric Association, 1987.
48. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 1992;49:881-7.
49. Mason BJ, Ownby RL. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectrums 2000;5:58-69.
50. Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 2003;12:14-48.
51. Besson J, Aeby F, Kasas A, Lehert P, Potgeiter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998;22:573-9.
52. Rubio G, Jimenez-Amero MA, Ponce G, Palomo T. Naltrexone vs. acamprosate: one year follow up of alcohol dependence treatment. Alcohol Alcohol 2001;36:419-25.
53. Kiefer F, Jahn H, Tarnaske T, Hauke H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention in alcoholism. Arch Gen Psychiatry 2003;60:92-9.
54. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001;25:1335-41.
55. Experts: acamprosate denial shouldn't slow Rx research. Alcoholism Drug Abuse Wkly 2002;14(27):1-2.
56. Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002;27:596-606.
57. Schädlich PK, Brecht JG. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Pharmacoeconomics 1998;13:719-30.
58. Palmer AJ, Neeser K, Weiss C, Brandt A, Comte S, Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol 2000;35:478-92.
59. Annemans L, Vanoverbeke N, Tecco J, D'Hooghe D. Economic evaluation of campral (acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. Eur Addiction Res 2000;6:71-8.
60. Foster RH, McClellan KJ. Acamprosate, pharmacoeconomic implications of therapy. Pharmacoeconomics 1999;16:743-55.
61. Food and Drug Administration. Psychopharmacological Drugs Advisory Committee (5/10/02). NDA 21-431 Acamprosate 333 mg tablets (Lipha Pharmaceuticals, Inc.) www.fda.gov/ohrms/dockets/ac/02/minutes/3857M1.pdf (accessed 2002 Jul 18).
62. Forest/Lipha acamprosate indication should be limited to abstinent patients. FDA Pink Sheets 2002;64(19):24.